Qiming Venture Partners and Its Investors Named to 36Kr's 2025 China Equity Investment Industry Lists
Investment firms focused on technological innovation are well-positioned to stand out in this wave of industrial upgrading.
36Kr recently released its 2025 China Equity Investment Industry Institutional Rankings. The series comprises both institutional and individual investor lists.
Qiming Venture Partners, along with Duane Kuang, Founding Managing Partner; William Hu, Managing Partner; and Alex Zhou, Managing Partner, were all named to the rankings.
Qiming Venture Partners
Named to
Top 5 Venture Capital Firms in China
Top 10 Most Influential Venture Capital Firms in China
Duane Kuang Founding Managing Partner, Qiming Venture Partners
William Hu Managing Partner, Qiming Venture Partners
Alex Zhou Managing Partner, Qiming Venture Partners
Named to
Top 100 Most Founder-Friendly Investors in China
In China's equity investment market in 2024, the standout growth segments centered on hard tech — specifically artificial intelligence, embodied AI, and advanced manufacturing. In Q1 2025, investment firms entered a critical transition period; those focused on technological innovation are positioned to stand out in this wave of industrial upgrading.
Source | 36Kr
Past Coverage
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), GenScript ProBio (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.